24/7 Market News – (NASDAQ:MITO) – Shares are currently at .39 cents and climbing with more than 1500 trades already in the pre-market.

(NASDAQ:MITO) – Shares are moving this morning up more than 45% on news of positive Phase 1 study results showing upper neuron improvement and safety.

Stealth BioTherapeutics Presents New SBT-272 Data Demonstrating Improvement in Upper Motor Neuron Function in ALS Disease Model at Keystone Neurodegeneration Symposium

24/7 Marketnews.com

SBT-272 improved neuronal health, superior to other approved and investigational agents

Phase 1 study to evaluate safety and tolerability of SBT-272 in healthy volunteers is underway Stealth BioTherapeutics Corp a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today the presentation of new SBT-272 preclinical data demonstrating functional improvement in upper motor neurons with TDP-43 pathology, which plays a significant role in both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The data were presented at the Keystone Neurodegeneration Symposium in Keystone, CO held June 5-9,2022. A Phase 1 study to evaluate the safety and tolerability of SBT-272 in healthy volunteers is underway.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.